Matthew Jenusaitis
Known title: DirectorCIK: 0001357864
Matthew Jenusaitis's purchase track record
Matthew Jenusaitis has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/19/2024 | NVNO | $24K | +14.6% | +60.1% | +1.7% |
| 8/25/2021 | NVNO | $10K | -6.2% | -42.6% | -6.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NVNO | ▲ Buy | Open Market | 9,620 | $24K | 12/19/2024 | View on chart |
| NVNO | ▲ Buy | Option Exercise | 1,041 | — | 9/13/2022 | View on chart |
| NVNO | ▲ Buy | Option Exercise | 1,042 | — | 9/13/2021 | View on chart |
| NVNO | ▲ Buy | Open Market | 1,300 | $10K | 8/25/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
enVVeno Medical to Showcase enVVe System at VEINS 2026 Summit
enVVeno Medical Corporation announced that its first-in-class enVVe system will be featured at The VEINS 2026 Innovation Summit. This event highlights the company's progress as it moves toward a U.S. pivotal trial for its medical technology. The announcement serves as a key milestone in the development timeline for the device.
enVVeno Medical to Showcase enVVe System at VEINS 2026 Summit. enVVeno Medical Corporation announced that its first-in-class enVVe system will be featured at The VEINS 2026 Innovation Summit. This event highlights the company's progress as it moves toward a U.S. pivotal trial for its medical technology. The announcement serves as a key milestone in the development timeline for the device.